Oncolytic viruses (OVs) are an emerging class of cancer therapeutics that offer the benefits
of selective replication in tumour cells, delivery of multiple eukaryotic transgene payloads …

Dysregulation of the Notch signaling pathway, which is highly conserved across species,
can drive aberrant epigenetic modification, transcription, and translation. Defective gene …

Immune checkpoint blockade (ICB) therapy shows excellent efficacy against malignancies;
however, insufficient tumor immunogenicity and the immunosuppressive tumor …

Cancer radio-immunotherapy, integrating external/internal radiation therapy with immuno-
oncology treatments, emerges in the current management of cancer. A growing number of …

Glioblastoma (GBM) is a common and highly malignant primary tumor of the central nervous
system in adults. Ever more recent papers are focusing on understanding the role of the …

In 2015, oncolytic virotherapy was approved for clinical use, and in 2017, recombinant
adeno-associated virus (AAV) delivery was also approved. However, systemic …

Rodent brain tumor models have been useful for developing effective therapies for
glioblastomas (GBMs). In this review, we first discuss the 3 most commonly used rat brain …

Simple Summary Glioblastoma (GBM) is the most severe and aggressive form of primary
brain tumor with a poor prognosis. Currently, the treatment for GBM treatment involves …

Introduction To overcome the challenge of treating malignant brain tumors, oncolytic viruses
(OVs) represent an innovative therapeutic approach, featuring unique mechanisms of action …

Glioblastoma is a highly aggressive form of brain cancer characterized by the abundance of
myeloid lineage cells in the tumor microenvironment. Tumor-associated macrophages and …